-
1
-
-
77951205622
-
Low sensitivity in clinical diagnoses of dementia with Lewy bodies
-
2839040 19795154
-
Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol. 2010;257:359-66.
-
(2010)
J Neurol.
, vol.257
, pp. 359-366
-
-
Nelson, P.T.1
Jicha, G.A.2
Kryscio, R.J.3
Abner, E.L.4
Schmitt, F.A.5
Cooper, G.6
-
2
-
-
84896479748
-
The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies
-
23521899
-
Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2013;44:673-83.
-
(2013)
Psychol Med.
, vol.44
, pp. 673-683
-
-
Vann Jones, S.A.1
O'Brien, J.T.2
-
3
-
-
84887472931
-
The incidence and prevalence of dementia with Lewy bodies is underestimated
-
23985217
-
Boot B. The incidence and prevalence of dementia with Lewy bodies is underestimated. Psychol Med. 2013;43:2687-8.
-
(2013)
Psychol Med.
, vol.43
, pp. 2687-2688
-
-
Boot, B.1
-
4
-
-
33144489150
-
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium
-
1:STN:280:DC%2BD2Mnpt1GqsQ%3D%3D 16237129
-
McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-72.
-
(2005)
Neurology.
, vol.65
, pp. 1863-1872
-
-
McKeith, I.G.1
Dickson, D.W.2
Lowe, J.3
Emre, M.4
O'Brien, J.T.5
Feldman, H.6
-
5
-
-
84880850040
-
Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: Pathophysiology, clinical features, and pharmacological management
-
1:CAS:528:DC%2BC3sXhvVaju77L 23681401
-
Ballard C, Aarsland D, Francis P, Corbett A. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging. 2013;30:603-11.
-
(2013)
Drugs Aging.
, vol.30
, pp. 603-611
-
-
Ballard, C.1
Aarsland, D.2
Francis, P.3
Corbett, A.4
-
6
-
-
27844469751
-
A systematic review of prevalence studies of dementia in Parkinson's disease
-
16041803
-
Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord. 2005;20:1255-63.
-
(2005)
Mov Disord.
, vol.20
, pp. 1255-1263
-
-
Aarsland, D.1
Zaccai, J.2
Brayne, C.3
-
7
-
-
35748959415
-
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
-
17568013
-
Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-204.
-
(2007)
Neurology.
, vol.69
, pp. 2197-2204
-
-
Schneider, J.A.1
Arvanitakis, Z.2
Bang, W.3
Bennett, D.A.4
-
8
-
-
0033009837
-
Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease
-
1:STN:280:DyaK1MzivFKqsA%3D%3D 10401449
-
Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry. 1999;156:1039-45.
-
(1999)
Am J Psychiatry.
, vol.156
, pp. 1039-1045
-
-
Ballard, C.1
Holmes, C.2
McKeith, I.3
Neill, D.4
O'Brien, J.5
Cairns, N.6
-
9
-
-
0034966777
-
Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease
-
1:STN:280:DC%2BD3MzntlKnsg%3D%3D 11405813
-
Ballard C, O'Brien J, Gray A, Cormack F, Ayre G, Rowan E, et al. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol. 2001;58:977-82.
-
(2001)
Arch Neurol.
, vol.58
, pp. 977-982
-
-
Ballard, C.1
O'Brien, J.2
Gray, A.3
Cormack, F.4
Ayre, G.5
Rowan, E.6
-
10
-
-
84884481920
-
Risk factors for dementia with Lewy bodies: A case-control study
-
3908463 1:CAS:528:DC%2BC3sXhtlagu73P 23892702
-
Boot BP, Orr CF, Ahlskog JE, Ferman TJ, Roberts R, Pankratz VS, et al. Risk factors for dementia with Lewy bodies: a case-control study. Neurology. 2013;81:833-40.
-
(2013)
Neurology.
, vol.81
, pp. 833-840
-
-
Boot, B.P.1
Orr, C.F.2
Ahlskog, J.E.3
Ferman, T.J.4
Roberts, R.5
Pankratz, V.S.6
-
11
-
-
84856805730
-
Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease - Measured from a fixed cognitive level
-
22327504
-
Stubendorff K, Hansson O, Minthon L, Londos E. Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease - measured from a fixed cognitive level. Dement Geriatr Cogn Disord. 2011;32:408-16.
-
(2011)
Dement Geriatr Cogn Disord.
, vol.32
, pp. 408-416
-
-
Stubendorff, K.1
Hansson, O.2
Minthon, L.3
Londos, E.4
-
12
-
-
4344613595
-
Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies
-
15312280
-
Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17:164-71.
-
(2004)
J Geriatr Psychiatry Neurol.
, vol.17
, pp. 164-171
-
-
Aarsland, D.1
Mosimann, U.P.2
McKeith, I.G.3
-
13
-
-
10044283107
-
Rivastigmine for dementia associated with Parkinson's disease
-
1:CAS:528:DC%2BD2cXhtVGksbnF 15590953
-
Emre M, Aarsland D, Albanese A, Byrne E, Deuschl G, De Deyn P, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351:2509-18.
-
(2004)
N Engl J Med.
, vol.351
, pp. 2509-2518
-
-
Emre, M.1
Aarsland, D.2
Albanese, A.3
Byrne, E.4
Deuschl, G.5
De Deyn, P.6
-
14
-
-
84861987193
-
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease
-
22419314
-
Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;3:CD006504.
-
(2012)
Cochrane Database Syst Rev.
, vol.3
, pp. 006504
-
-
Rolinski, M.1
Fox, C.2
Maidment, I.3
McShane, R.4
-
15
-
-
34447633719
-
Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: Similarities and differences
-
1:CAS:528:DC%2BD2sXnvFKksbc%3D 17656830
-
Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. J Alzheimers Dis. 2007;11:509-19.
-
(2007)
J Alzheimers Dis.
, vol.11
, pp. 509-519
-
-
Emre, M.1
Cummings, J.L.2
Lane, R.M.3
-
16
-
-
77950511411
-
Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo
-
1:CAS:528:DC%2BC3cXltV2nu7g%3D 20181924
-
Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885-92.
-
(2010)
Neurology.
, vol.74
, pp. 885-892
-
-
Klein, J.C.1
Eggers, C.2
Kalbe, E.3
Weisenbach, S.4
Hohmann, C.5
Vollmar, S.6
-
17
-
-
0842304136
-
DLB fluctuations: Specific features that reliably differentiate DLB from AD and normal aging
-
1:STN:280:DC%2BD2c%2FksVyjsA%3D%3D 14745051
-
Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004;62:181-7.
-
(2004)
Neurology.
, vol.62
, pp. 181-187
-
-
Ferman, T.J.1
Smith, G.E.2
Boeve, B.F.3
Ivnik, R.J.4
Petersen, R.C.5
Knopman, D.6
-
18
-
-
84864426175
-
Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial
-
1:CAS:528:DC%2BC38XhtVOgsLbF 22829268
-
Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72:41-52.
-
(2012)
Ann Neurol.
, vol.72
, pp. 41-52
-
-
Mori, E.1
Ikeda, M.2
Kosaka, K.3
-
19
-
-
84884680030
-
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: Results from a 52-week, open-label, multicenter extension study
-
1:CAS:528:DC%2BC3sXhsFelsLvK 23949147
-
Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013;36:229-41.
-
(2013)
Dement Geriatr Cogn Disord.
, vol.36
, pp. 229-241
-
-
Ikeda, M.1
Mori, E.2
Kosaka, K.3
Iseki, E.4
Hashimoto, M.5
Matsukawa, N.6
-
20
-
-
80051500137
-
The Movement Disorder Society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's disease
-
4020145 22021174
-
Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011;26:S42-80.
-
(2011)
Mov Disord.
, vol.26
, pp. 42-80
-
-
Seppi, K.1
Weintraub, D.2
Coelho, M.3
Perez-Lloret, S.4
Fox, S.H.5
Katzenschlager, R.6
-
21
-
-
84877923028
-
Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies
-
23554107
-
Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord. 2013;28:597-604.
-
(2013)
Mov Disord.
, vol.28
, pp. 597-604
-
-
Postuma, R.B.1
Gagnon, J.F.2
Pelletier, A.3
Montplaisir, J.4
-
22
-
-
84858707220
-
MIBG scintigraphy in differential diagnosis of Parkinsonism: A meta-analysis
-
21792729
-
Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43-55.
-
(2012)
Clin Auton Res.
, vol.22
, pp. 43-55
-
-
Treglia, G.1
Cason, E.2
Stefanelli, A.3
Cocciolillo, F.4
Di Giuda, D.5
Fagioli, G.6
-
23
-
-
77953272427
-
Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB)
-
2879079 20505440
-
Rosenbloom MH, Finley R, Scheinman MM, Feldman MD, Miller BL, Rabinovici GD. Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB). Alzheimer Dis Assoc Disord. 2010;24:209-11.
-
(2010)
Alzheimer Dis Assoc Disord.
, vol.24
, pp. 209-211
-
-
Rosenbloom, M.H.1
Finley, R.2
Scheinman, M.M.3
Feldman, M.D.4
Miller, B.L.5
Rabinovici, G.D.6
-
24
-
-
84892367733
-
Failure to manage constipation in Parkinson's disease. A review of medical services: A patients perspective
-
Lawrence J, Parmenter T, McDonald T. Failure to manage constipation in Parkinson's disease. A review of medical services: a patients perspective. Movement Disorders. 2013;28 Suppl 1:187.
-
(2013)
Movement Disorders
, vol.281
, pp. 187
-
-
Lawrence, J.1
Parmenter, T.2
McDonald, T.3
-
25
-
-
0031001025
-
Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management
-
1:STN:280:DyaK2s3mt1Omuw%3D%3D 9108986
-
Jost WH. Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging. 1997;10:249-58.
-
(1997)
Drugs Aging
, vol.10
, pp. 249-258
-
-
Jost, W.H.1
-
26
-
-
28044457416
-
Benefits of rivastigmine on attention in dementia associated with Parkinson disease
-
1:CAS:528:DC%2BD2MXhtFOhsL%2FO 16301500
-
Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65:1654-6.
-
(2005)
Neurology.
, vol.65
, pp. 1654-1656
-
-
Wesnes, K.A.1
McKeith, I.2
Edgar, C.3
Emre, M.4
Lane, R.5
-
27
-
-
84870552882
-
Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia
-
1:STN:280:DC%2BC38fgvVSrtw%3D%3D 22806065
-
Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P. Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. Curr Neurol Neurosci Rep. 2012;12:492-501.
-
(2012)
Curr Neurol Neurosci Rep.
, vol.12
, pp. 492-501
-
-
Aarsland, D.1
Ballard, C.2
Rongve, A.3
Broadstock, M.4
Svenningsson, P.5
-
28
-
-
77956874908
-
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial
-
1:CAS:528:DC%2BC3cXhtFOntbvL 20729148
-
Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:969-77.
-
(2010)
Lancet Neurol.
, vol.9
, pp. 969-977
-
-
Emre, M.1
Tsolaki, M.2
Bonuccelli, U.3
Destee, A.4
Tolosa, E.5
Kutzelnigg, A.6
-
29
-
-
77955404787
-
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
-
2918470 1:CAS:528:DC%2BC3cXpslWqsLg%3D 20679638
-
Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448-55.
-
(2010)
Neurology.
, vol.75
, pp. 448-455
-
-
Weintraub, D.1
Mavandadi, S.2
Mamikonyan, E.3
Siderowf, A.D.4
Duda, J.E.5
Hurtig, H.I.6
-
30
-
-
80052284729
-
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study
-
21500280
-
Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011;26:1851-8.
-
(2011)
Mov Disord.
, vol.26
, pp. 1851-1858
-
-
Hanagasi, H.A.1
Gurvit, H.2
Unsalan, P.3
Horozoglu, H.4
Tuncer, N.5
Feyzioglu, A.6
-
31
-
-
78349310514
-
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
-
20880750
-
Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010;9:1200-13.
-
(2010)
Lancet Neurol.
, vol.9
, pp. 1200-1213
-
-
Kehagia, A.A.1
Barker, R.A.2
Robbins, T.W.3
-
32
-
-
0027102421
-
Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients
-
1486457
-
Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain. 1992;115 Pt 6:1701-25.
-
(1992)
Brain
, vol.1156
, pp. 1701-1725
-
-
Cooper, J.A.1
Sagar, H.J.2
Doherty, S.M.3
Jordan, N.4
Tidswell, P.5
Sullivan, E.V.6
-
33
-
-
84863880556
-
Cognitive impairment in patients with Parkinson's disease: Diagnosis, biomarkers, and treatment
-
22814541
-
Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11:697-707.
-
(2012)
Lancet Neurol.
, vol.11
, pp. 697-707
-
-
Svenningsson, P.1
Westman, E.2
Ballard, C.3
Aarsland, D.4
-
35
-
-
0032004958
-
Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease
-
1:CAS:528:DyaK1cXhvVaktbY%3D 9608603
-
Ohara K, Kondo N, Ohara K. Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:311-7.
-
(1998)
Prog Neuropsychopharmacol Biol Psychiatry.
, vol.22
, pp. 311-317
-
-
Ohara, K.1
Kondo, N.2
Ohara, K.3
-
36
-
-
54749151102
-
Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia
-
1:CAS:528:DC%2BD1cXhtlSktbzP 18841018
-
Sharp SI, Ballard CG, Ziabreva I, Piggott MA, Perry RH, Perry EK, et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord. 2008;26:330-8.
-
(2008)
Dement Geriatr Cogn Disord.
, vol.26
, pp. 330-338
-
-
Sharp, S.I.1
Ballard, C.G.2
Ziabreva, I.3
Piggott, M.A.4
Perry, R.H.5
Perry, E.K.6
-
37
-
-
84861561293
-
How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder
-
1:STN:280:DC%2BC38ngvVOqsA%3D%3D 22561644
-
Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain. 2012;135:1860-70.
-
(2012)
Brain.
, vol.135
, pp. 1860-1870
-
-
Postuma, R.B.1
Lang, A.E.2
Gagnon, J.F.3
Pelletier, A.4
Montplaisir, J.Y.5
-
38
-
-
84899846171
-
Mild parkinsonian signs in the elderly - Is there an association with PD? Crossectional findings in 992 individuals
-
3968033 24675747
-
Lerche S, Hobert M, Brockmann K, Wurster I, Gaenslen A, Hasmann S, et al. Mild parkinsonian signs in the elderly - is there an association with PD? Crossectional findings in 992 individuals. PLoS One. 2014;9:e92878.
-
(2014)
PLoS One.
, vol.9
, pp. 92878
-
-
Lerche, S.1
Hobert, M.2
Brockmann, K.3
Wurster, I.4
Gaenslen, A.5
Hasmann, S.6
-
39
-
-
18844481916
-
Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies
-
1:STN:280:DC%2BD3c7otlaitw%3D%3D 10720273
-
McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050-8.
-
(2000)
Neurology.
, vol.54
, pp. 1050-1058
-
-
McKeith, I.G.1
Ballard, C.G.2
Perry, R.H.3
Ince, P.G.4
O'Brien, J.T.5
Neill, D.6
-
40
-
-
0036182403
-
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies
-
1:CAS:528:DC%2BD38XhtFOruro%3D 11844887
-
Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13:67-73.
-
(2002)
Dement Geriatr Cogn Disord.
, vol.13
, pp. 67-73
-
-
Cummings, J.L.1
Street, J.2
Masterman, D.3
Clark, W.S.4
-
41
-
-
78651400870
-
Treating neuropsychiatric symptoms in dementia with Lewy bodies: A randomized controlled-trial
-
20625270
-
Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010;24:360-4.
-
(2010)
Alzheimer Dis Assoc Disord.
, vol.24
, pp. 360-364
-
-
Culo, S.1
Mulsant, B.H.2
Rosen, J.3
Mazumdar, S.4
Blakesley, R.E.5
Houck, P.R.6
-
42
-
-
27744564717
-
Antidepressant studies in Parkinson's disease: A review and meta-analysis
-
1989731 15954137
-
Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord. 2005;20:1161-9.
-
(2005)
Mov Disord.
, vol.20
, pp. 1161-1169
-
-
Weintraub, D.1
Morales, K.H.2
Moberg, P.J.3
Bilker, W.B.4
Balderston, C.5
Duda, J.E.6
-
43
-
-
0344825104
-
Systematic review of antidepressant therapies in Parkinson's disease
-
1:STN:280:DC%2BD3srntFWrsA%3D%3D 14643994
-
Chung TH, Deane KH, Ghazi-Noori S, Rickards H, Clarke CE. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord. 2003;10:59-65.
-
(2003)
Parkinsonism Relat Disord.
, vol.10
, pp. 59-65
-
-
Chung, T.H.1
Deane, K.H.2
Ghazi-Noori, S.3
Rickards, H.4
Clarke, C.E.5
-
44
-
-
67650649472
-
Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy
-
19604326
-
Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9:56-61.
-
(2009)
Psychogeriatrics.
, vol.9
, pp. 56-61
-
-
Takahashi, S.1
Mizukami, K.2
Yasuno, F.3
Asada, T.4
-
45
-
-
38749140624
-
Management of non-motor symptoms in advanced Parkinson disease
-
17804018
-
Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci. 2008;266:216-28.
-
(2008)
J Neurol Sci.
, vol.266
, pp. 216-228
-
-
Truong, D.D.1
Bhidayasiri, R.2
Wolters, E.3
-
46
-
-
34447337016
-
The phenomenology of psychotic features in dementia with Lewy bodies (DLB) and Alheimer's diesease (AD)
-
Ferman TJ, Boeve BF, Smith GE, Graff-Radford NR. The phenomenology of psychotic features in dementia with Lewy bodies (DLB) and Alheimer's diesease (AD). Neurology. 2005;64:A257.
-
(2005)
Neurology.
, vol.64
, pp. 257
-
-
Ferman, T.J.1
Boeve, B.F.2
Smith, G.E.3
Graff-Radford, N.R.4
-
47
-
-
77952430689
-
Management of behavioral problems in Alzheimer's disease
-
20096151
-
Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, et al. Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr. 2010;22:346-72.
-
(2010)
Int Psychogeriatr.
, vol.22
, pp. 346-372
-
-
Gauthier, S.1
Cummings, J.2
Ballard, C.3
Brodaty, H.4
Grossberg, G.5
Robert, P.6
-
48
-
-
84864651983
-
Pareidolias: Complex visual illusions in dementia with Lewy bodies
-
3407420 22649179
-
Uchiyama M, Nishio Y, Yokoi K, Hirayama K, Imamura T, Shimomura T, et al. Pareidolias: complex visual illusions in dementia with Lewy bodies. Brain. 2012;135:2458-69.
-
(2012)
Brain.
, vol.135
, pp. 2458-2469
-
-
Uchiyama, M.1
Nishio, Y.2
Yokoi, K.3
Hirayama, K.4
Imamura, T.5
Shimomura, T.6
-
49
-
-
77957262214
-
Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease
-
1:CAS:528:DC%2BC3cXht1WhtrjF 20869620
-
Wood LD, Neumiller JJ, Setter SM, Dobbins EK. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am J Geriatr Pharmacother. 2010;8:294-315.
-
(2010)
Am J Geriatr Pharmacother.
, vol.8
, pp. 294-315
-
-
Wood, L.D.1
Neumiller, J.J.2
Setter, S.M.3
Dobbins, E.K.4
-
50
-
-
33644922637
-
Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials
-
16505124
-
Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210.
-
(2006)
Am J Geriatr Psychiatry.
, vol.14
, pp. 191-210
-
-
Schneider, L.S.1
Dagerman, K.2
Insel, P.S.3
-
51
-
-
0036163983
-
Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities
-
11813276
-
Ballard C, Powell I, James I, Reichelt K, Myint P, Potkins D, et al. Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. Int J Geriatr Psychiatry. 2002;17:140-5.
-
(2002)
Int J Geriatr Psychiatry.
, vol.17
, pp. 140-145
-
-
Ballard, C.1
Powell, I.2
James, I.3
Reichelt, K.4
Myint, P.5
Potkins, D.6
-
52
-
-
79953688283
-
Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease
-
1:CAS:528:DC%2BC3MXltlGns70%3D 21474930
-
Musicco M, Palmer K, Russo A, Caltagirone C, Adorni F, Pettenati C, et al. Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord. 2011;31:218-24.
-
(2011)
Dement Geriatr Cogn Disord.
, vol.31
, pp. 218-224
-
-
Musicco, M.1
Palmer, K.2
Russo, A.3
Caltagirone, C.4
Adorni, F.5
Pettenati, C.6
-
53
-
-
58649100881
-
The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial
-
1:CAS:528:DC%2BD1MXisFCgu7o%3D 19138567
-
Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8:151-7.
-
(2009)
Lancet Neurol.
, vol.8
, pp. 151-157
-
-
Ballard, C.1
Hanney, M.L.2
Theodoulou, M.3
Douglas, S.4
McShane, R.5
Kossakowski, K.6
-
54
-
-
84865851282
-
Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia
-
22952073
-
Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169:946-53.
-
(2012)
Am J Psychiatry.
, vol.169
, pp. 946-953
-
-
Brodaty, H.1
Arasaratnam, C.2
-
55
-
-
84869161573
-
Nonpharmacologic management of behavioral symptoms in dementia
-
3711645 1:CAS:528:DC%2BC38XhvVCmtrjP 23168825
-
Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308:2020-9.
-
(2012)
JAMA.
, vol.308
, pp. 2020-2029
-
-
Gitlin, L.N.1
Kales, H.C.2
Lyketsos, C.G.3
-
56
-
-
1442357988
-
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome
-
14744180
-
Ballard CG, Thomas A, Fossey J, Lee L, Jacoby R, Lana MM, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004;65:114-9.
-
(2004)
J Clin Psychiatry.
, vol.65
, pp. 114-119
-
-
Ballard, C.G.1
Thomas, A.2
Fossey, J.3
Lee, L.4
Jacoby, R.5
Lana, M.M.6
-
57
-
-
19544378167
-
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias
-
15889951
-
Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66:633-7.
-
(2005)
J Clin Psychiatry.
, vol.66
, pp. 633-637
-
-
Aarsland, D.1
Perry, R.2
Larsen, J.P.3
McKeith, I.G.4
O'Brien, J.T.5
Perry, E.K.6
-
58
-
-
33745737632
-
Neuroleptic drugs in dementia: Benefits and harm
-
1:CAS:528:DC%2BD28Xkslelu7Y%3D 16715057
-
Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7:492-500.
-
(2006)
Nat Rev Neurosci.
, vol.7
, pp. 492-500
-
-
Ballard, C.1
Howard, R.2
-
59
-
-
25144465916
-
Atypical antipsychotics and parkinsonism
-
1:CAS:528:DC%2BD2MXhtFWgu7jP 16157833
-
Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882-8.
-
(2005)
Arch Intern Med.
, vol.165
, pp. 1882-1888
-
-
Rochon, P.A.1
Stukel, T.A.2
Sykora, K.3
Gill, S.4
Garfinkel, S.5
Anderson, G.M.6
-
60
-
-
81155123777
-
Consultation-liaison psychiatry and prevention of severe neuroleptic sensitivity reactions in dementia with Lewy bodies
-
22077306
-
Hassan I. Consultation-liaison psychiatry and prevention of severe neuroleptic sensitivity reactions in dementia with Lewy bodies. Australas Psychiatry. 2011;19:536-7.
-
(2011)
Australas Psychiatry.
, vol.19
, pp. 536-537
-
-
Hassan, I.1
-
61
-
-
0036087948
-
Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies
-
1:CAS:528:DC%2BD38XlsFSrs74%3D 12088163
-
Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002;63:513-5.
-
(2002)
J Clin Psychiatry.
, vol.63
, pp. 513-515
-
-
Fernandez, H.H.1
Trieschmann, M.E.2
Burke, M.A.3
Friedman, J.H.4
-
62
-
-
34247487794
-
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism
-
1:CAS:528:DC%2BD2sXktlSms7s%3D Alzheimer's Disease Cooperative Study G 17452579
-
Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study G. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356-63.
-
(2007)
Neurology.
, vol.68
, pp. 1356-1363
-
-
Kurlan, R.1
Cummings, J.2
Raman, R.3
Thal, L.4
-
63
-
-
84883693104
-
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease
-
3990263 23896958
-
Lopez O, Becker J, Chang Y, Sweet R, Aizenstein H, Snitz B, et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry. 2013;170:1051-8.
-
(2013)
Am J Psychiatry.
, vol.170
, pp. 1051-1058
-
-
Lopez, O.1
Becker, J.2
Chang, Y.3
Sweet, R.4
Aizenstein, H.5
Snitz, B.6
-
65
-
-
33751170883
-
Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis
-
1:CAS:528:DC%2BD28Xht1eqsLrE 17070675
-
Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17:165-71.
-
(2007)
Eur Neuropsychopharmacol.
, vol.17
, pp. 165-171
-
-
Frieling, H.1
Hillemacher, T.2
Ziegenbein, M.3
Neundorfer, B.4
Bleich, S.5
-
66
-
-
33749618085
-
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
-
1:CAS:528:DC%2BD28XhtVyhtrfE 17035647
-
Schneider L, Tariot P, Dagerman K, Davis S, Hsiao J, Ismail M, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355:1525-38.
-
(2006)
N Engl J Med.
, vol.355
, pp. 1525-1538
-
-
Schneider, L.1
Tariot, P.2
Dagerman, K.3
Davis, S.4
Hsiao, J.5
Ismail, M.6
-
67
-
-
0038485957
-
Long-term outcome of quetiapine use for psychosis among Parkinsonian patients
-
12722164
-
Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003;18:510-4.
-
(2003)
Mov Disord.
, vol.18
, pp. 510-514
-
-
Fernandez, H.H.1
Trieschmann, M.E.2
Burke, M.A.3
Jacques, C.4
Friedman, J.H.5
-
68
-
-
0035241276
-
Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
-
1:STN:280:DC%2BD3MzjslKgsA%3D%3D 11215574
-
Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001;16:135-9.
-
(2001)
Mov Disord.
, vol.16
, pp. 135-139
-
-
Factor, S.A.1
Friedman, J.H.2
Lannon, M.C.3
Oakes, D.4
Bourgeois, K.5
-
69
-
-
1942421734
-
Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up
-
1763590 1:STN:280:DC%2BD2c3ivVGmtQ%3D%3D 15090561
-
Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689-95.
-
(2004)
J Neurol Neurosurg Psychiatry.
, vol.75
, pp. 689-695
-
-
Pollak, P.1
Tison, F.2
Rascol, O.3
Destee, A.4
Pere, J.J.5
Senard, J.M.6
-
70
-
-
20844433549
-
Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis
-
1:CAS:528:DC%2BD2cXmvVarsrc%3D 15319699
-
Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004;27:153-6.
-
(2004)
Clin Neuropharmacol.
, vol.27
, pp. 153-156
-
-
Morgante, L.1
Epifanio, A.2
Spina, E.3
Zappia, M.4
Di Rosa, A.E.5
Marconi, R.6
-
71
-
-
33750910746
-
Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson's disease psychosis
-
1:CAS:528:DC%2BD28XhtFymtL%2FN 17095896
-
Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol. 2006;29:331-7.
-
(2006)
Clin Neuropharmacol.
, vol.29
, pp. 331-337
-
-
Merims, D.1
Balas, M.2
Peretz, C.3
Shabtai, H.4
Giladi, N.5
-
72
-
-
80055083817
-
The Movement Disorder Society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson's disease
-
22021173
-
Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26:S2-41.
-
(2011)
Mov Disord.
, vol.26
, pp. 2-41
-
-
Fox, S.H.1
Katzenschlager, R.2
Lim, S.Y.3
Ravina, B.4
Seppi, K.5
Coelho, M.6
-
73
-
-
84895904524
-
Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial
-
1:CAS:528:DC%2BC3sXhslaitL%2FM 24183563
-
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533-40.
-
(2014)
Lancet.
, vol.383
, pp. 533-540
-
-
Cummings, J.1
Isaacson, S.2
Mills, R.3
Williams, H.4
Chi-Burris, K.5
Corbett, A.6
-
75
-
-
84857404382
-
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: Cluster randomised clinical trial
-
3137923 21765198
-
Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065.
-
(2011)
BMJ.
, vol.343
, pp. 4065
-
-
Husebo, B.S.1
Ballard, C.2
Sandvik, R.3
Nilsen, O.B.4
Aarsland, D.5
-
76
-
-
33645571637
-
Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: Cluster randomised trial
-
1420717 16543297
-
Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332:756-61.
-
(2006)
BMJ.
, vol.332
, pp. 756-761
-
-
Fossey, J.1
Ballard, C.2
Juszczak, E.3
James, I.4
Alder, N.5
Jacoby, R.6
-
77
-
-
62549128208
-
Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: A cluster-randomised trial
-
19282246
-
Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8:317-25.
-
(2009)
Lancet Neurol.
, vol.8
, pp. 317-325
-
-
Chenoweth, L.1
King, M.T.2
Jeon, Y.H.3
Brodaty, H.4
Stein-Parbury, J.5
Norman, R.6
-
78
-
-
84857662132
-
The enriched opportunities programme for people with dementia: A cluster-randomised controlled trial in 10 extra care housing schemes
-
21702705
-
Brooker DJ, Argyle E, Scally AJ, Clancy D. The enriched opportunities programme for people with dementia: a cluster-randomised controlled trial in 10 extra care housing schemes. Aging Mental Health. 2011;15:1008-17.
-
(2011)
Aging Mental Health.
, vol.15
, pp. 1008-1017
-
-
Brooker, D.J.1
Argyle, E.2
Scally, A.J.3
Clancy, D.4
-
79
-
-
77956175253
-
Levodopa response in dementia with lewy bodies: A 1-year follow-up study
-
20615745
-
Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, et al. Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010;16:522-6.
-
(2010)
Parkinsonism Relat Disord.
, vol.16
, pp. 522-526
-
-
Lucetti, C.1
Logi, C.2
Del Dotto, P.3
Berti, C.4
Ceravolo, R.5
Baldacci, F.6
-
80
-
-
23944501017
-
The role of levodopa in the management of dementia with Lewy bodies
-
1739807 1:STN:280:DC%2BD2MvktV2nsg%3D%3D 16107351
-
Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76:1200-3.
-
(2005)
J Neurol Neurosurg Psychiatry.
, vol.76
, pp. 1200-1203
-
-
Molloy, S.1
McKeith, I.G.2
O'Brien, J.T.3
Burn, D.J.4
-
81
-
-
61449231824
-
Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies
-
18823039
-
Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23:2248-50.
-
(2008)
Mov Disord.
, vol.23
, pp. 2248-2250
-
-
Goldman, J.G.1
Goetz, C.G.2
Brandabur, M.3
Sanfilippo, M.4
Stebbins, G.T.5
-
82
-
-
79955042174
-
Dopamine agonist-triggered pathological behaviors: Surveillance in the PD clinic reveals high frequencies
-
1:STN:280:DC%2BC3MvltlOrug%3D%3D 21310646
-
Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, Josephs KA, et al. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat Disord. 2011;17:260-4.
-
(2011)
Parkinsonism Relat Disord.
, vol.17
, pp. 260-264
-
-
Hassan, A.1
Bower, J.H.2
Kumar, N.3
Matsumoto, J.Y.4
Fealey, R.D.5
Josephs, K.A.6
-
83
-
-
0030700751
-
Constipation in Parkinson's disease: Objective assessment and response to psyllium
-
1:STN:280:DyaK1c%2FmtFKitQ%3D%3D 9399219
-
Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord. 1997;12:946-51.
-
(1997)
Mov Disord.
, vol.12
, pp. 946-951
-
-
Ashraf, W.1
Pfeiffer, R.F.2
Park, F.3
Lof, J.4
Quigley, E.M.5
-
84
-
-
34548272597
-
Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study
-
17566120
-
Zangaglia R, Martignoni E, Glorioso M, Ossola M, Riboldazzi G, Calandrella D, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord. 2007;22:1239-44.
-
(2007)
Mov Disord
, vol.22
, pp. 1239-1244
-
-
Zangaglia, R.1
Martignoni, E.2
Glorioso, M.3
Ossola, M.4
Riboldazzi, G.5
Calandrella, D.6
-
85
-
-
34547683268
-
Non-motor dysfunction in Parkinson's disease
-
17349813
-
Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2007;13:323-32.
-
(2007)
Parkinsonism Relat Disord.
, vol.13
, pp. 323-332
-
-
Ziemssen, T.1
Reichmann, H.2
-
86
-
-
29344466431
-
Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients
-
16398909
-
Kay GG, Abou-Donia MB, Messer Jr WS, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53:2195-201.
-
(2005)
J Am Geriatr Soc.
, vol.53
, pp. 2195-2201
-
-
Kay, G.G.1
Abou-Donia, M.B.2
Messer, Jr.W.S.3
Murphy, D.G.4
Tsao, J.W.5
Ouslander, J.G.6
-
87
-
-
80755190051
-
Antimuscarinic drugs: Review of the cognitive impact when used to treat overactive bladder in elderly patients
-
21607875
-
Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep. 2011;12:351-7.
-
(2011)
Curr Urol Rep.
, vol.12
, pp. 351-357
-
-
Pagoria, D.1
O'Connor, R.C.2
Guralnick, M.L.3
-
88
-
-
0035010117
-
Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system
-
1:CAS:528:DC%2BD3MXks1Kgsrc%3D 11402632
-
Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol. 2001;41:636-44.
-
(2001)
J Clin Pharmacol.
, vol.41
, pp. 636-644
-
-
Todorova, A.1
Vonderheid-Guth, B.2
Dimpfel, W.3
-
89
-
-
0034892569
-
Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension
-
1737541 1:STN:280:DC%2BD3Mvms12gtg%3D%3D 11511713
-
Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71:371-4.
-
(2001)
J Neurol Neurosurg Psychiatry.
, vol.71
, pp. 371-374
-
-
Hussain, I.F.1
Brady, C.M.2
Swinn, M.J.3
Mathias, C.J.4
Fowler, C.J.5
-
90
-
-
2442672786
-
Autonomic dysfunction in dementia with Lewy bodies
-
1:STN:280:DC%2BD2c3mtFKqug%3D%3D 15159482
-
Thaisetthawatkul P, Boeve B, Benarroch E, Sandroni P, Ferman T, Petersen R, et al. Autonomic dysfunction in dementia with Lewy bodies. Neurology. 2004;62:1804-9.
-
(2004)
Neurology.
, vol.62
, pp. 1804-1809
-
-
Thaisetthawatkul, P.1
Boeve, B.2
Benarroch, E.3
Sandroni, P.4
Ferman, T.5
Petersen, R.6
-
91
-
-
84867025905
-
The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia
-
3462171 1:CAS:528:DC%2BC38XhsFSktLzN 23049679
-
Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS One. 2012;7:e45451.
-
(2012)
PLoS One.
, vol.7
, pp. 45451
-
-
Stubendorff, K.1
Aarsland, D.2
Minthon, L.3
Londos, E.4
-
92
-
-
34748866218
-
Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease
-
17557339
-
Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007;22:1543-9.
-
(2007)
Mov Disord.
, vol.22
, pp. 1543-1549
-
-
Schoffer, K.L.1
Henderson, R.D.2
O'Maley, K.3
O'Sullivan, J.D.4
-
93
-
-
0141674889
-
Acetylcholinesterase inhibition: A novel approach in the treatment of neurogenic orthostatic hypotension
-
1738643 1:STN:280:DC%2BD3szps1WqtQ%3D%3D 12933939
-
Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74:1294-8.
-
(2003)
J Neurol Neurosurg Psychiatry.
, vol.74
, pp. 1294-1298
-
-
Singer, W.1
Opfer-Gehrking, T.L.2
McPhee, B.R.3
Hilz, M.J.4
Bharucha, A.E.5
Low, P.A.6
-
94
-
-
33645739276
-
Pyridostigmine treatment trial in neurogenic orthostatic hypotension
-
16476804
-
Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63:513-8.
-
(2006)
Arch Neurol.
, vol.63
, pp. 513-518
-
-
Singer, W.1
Sandroni, P.2
Opfer-Gehrking, T.L.3
Suarez, G.A.4
Klein, C.M.5
Hines, S.6
-
95
-
-
84870857795
-
Neurodegenerative disease and REM behavior disorder
-
22879077
-
Malhotra R, Avidan AY. Neurodegenerative disease and REM behavior disorder. Curr Treat Options Neurol. 2012;14:474-92.
-
(2012)
Curr Treat Options Neurol.
, vol.14
, pp. 474-492
-
-
Malhotra, R.1
Avidan, A.Y.2
-
96
-
-
0037114678
-
Modafinil for the treatment of daytime sleepiness in Parkinson's disease: A double-blind, randomized, crossover, placebo-controlled polygraphic trial
-
1:STN:280:DC%2BD38jislWktA%3D%3D 12489899
-
Hogl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25:905-9.
-
(2002)
Sleep.
, vol.25
, pp. 905-909
-
-
Hogl, B.1
Saletu, M.2
Brandauer, E.3
Glatzl, S.4
Frauscher, B.5
Seppi, K.6
-
97
-
-
84892365959
-
Safety, tolerability, and efficacy of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies
-
Kuntz K, Boeve B, Drubach D, Allen L, Drubach D. Safety, tolerability, and efficacy of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies. Neurology. 2012;78:P04.192.
-
(2012)
Neurology.
, vol.78
, pp. 04192
-
-
Kuntz, K.1
Boeve, B.2
Drubach, D.3
Allen, L.4
Drubach, D.5
-
98
-
-
80055077766
-
Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies
-
3162640 1:STN:280:DC%2BC3Mjps1Kgtg%3D%3D 21849645
-
Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77:875-82.
-
(2011)
Neurology.
, vol.77
, pp. 875-882
-
-
Ferman, T.J.1
Boeve, B.F.2
Smith, G.E.3
Lin, S.C.4
Silber, M.H.5
Pedraza, O.6
-
99
-
-
84881546787
-
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder
-
3745815 1:STN:280:DC%2BC3svksFGlsQ%3D%3D 23474058
-
Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14:754-62.
-
(2013)
Sleep Med.
, vol.14
, pp. 754-762
-
-
Boeve, B.F.1
Silber, M.H.2
Ferman, T.J.3
Lin, S.C.4
Benarroch, E.E.5
Schmeichel, A.M.6
-
100
-
-
84855643179
-
A novel therapy for REM sleep behavior disorder (RBD)
-
3227710 22171203
-
Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med. 2011;7:639-44A.
-
(2011)
J Clin Sleep Med.
, vol.7
, pp. 639-44A
-
-
Howell, M.J.1
Arneson, P.A.2
Schenck, C.H.3
-
101
-
-
0041562707
-
Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: Results in 14 patients
-
14592300
-
Boeve B, Silber M, Ferman T. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4:281-4.
-
(2003)
Sleep Med.
, vol.4
, pp. 281-284
-
-
Boeve, B.1
Silber, M.2
Ferman, T.3
-
102
-
-
24344486006
-
Melatonin for sleep disturbances in Parkinson's disease
-
16084125
-
Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med. 2005;6:459-66.
-
(2005)
Sleep Med.
, vol.6
, pp. 459-466
-
-
Dowling, G.A.1
Mastick, J.2
Colling, E.3
Carter, J.H.4
Singer, C.M.5
Aminoff, M.J.6
-
103
-
-
34249072817
-
Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study
-
1:CAS:528:DC%2BD2sXlvF2isrw%3D 17404779
-
Medeiros CA, De Bruin Carvalhedo PF, Lopes LA, Magalhaes MC, de Lourdes Seabra M, de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol. 2007;254:459-64.
-
(2007)
J Neurol.
, vol.254
, pp. 459-464
-
-
Medeiros, C.A.1
De Bruin Carvalhedo, P.F.2
Lopes, L.A.3
Magalhaes, M.C.4
De Lourdes Seabra, M.5
De Bruin, V.M.6
-
104
-
-
84859423506
-
Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease
-
22290743
-
Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord. 2012;27:559-61.
-
(2012)
Mov Disord.
, vol.27
, pp. 559-561
-
-
Di Giacopo, R.1
Fasano, A.2
Quaranta, D.3
Della Marca, G.4
Bove, F.5
Bentivoglio, A.R.6
-
105
-
-
77749245945
-
Best practice guide for the treatment of REM sleep behavior disorder (RBD)
-
2823283 20191945
-
Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6:85-95.
-
(2010)
J Clin Sleep Med.
, vol.6
, pp. 85-95
-
-
Aurora, R.N.1
Zak, R.S.2
Maganti, R.K.3
Auerbach, S.H.4
Casey, K.R.5
Chowdhuri, S.6
-
106
-
-
1542264478
-
Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder
-
15164915
-
Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH. Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004;27:560-83.
-
(2004)
Sleep.
, vol.27
, pp. 560-583
-
-
Hening, W.A.1
Allen, R.P.2
Earley, C.J.3
Picchietti, D.L.4
Silber, M.H.5
|